InforCapital
News

Fremman Capital Raises Over €850M for European Buyout Fund

Fremman Capital surpasses €750M target, closing its second fund at €808M plus €45M. Firm's AUM now exceeds €3.6B. Article 8 classified fund targets mid-market.

AM
Alvaro de la Maza

Partner at Aninver

Key Takeaways

  • Sector: Healthcare, Healthtech & Medtech, Industrials, Technology, Software & Gaming.
  • Geography: Germany, Italy, United Kingdom, France, Spain.

Analysis

Fremman Capital, a European mid-market private equity firm, has successfully concluded fundraising for its second dedicated buyout vehicle, Fremman II MM, amassing €808 million. This figure, augmented by an additional €45 million from associated managed accounts, comfortably surpassed the firm's initial €750 million target. The successful close, achieved in less than 18 months, propels Fremman Capital's total assets under management beyond the €3.6 billion mark.

The robust investor appetite for Fremman II MM underscores a strong validation of the firm's investment strategy in the current economic climate, as noted by Ricardo de Serdio, Founder and CEO of Fremman Capital. The fund attracted a diverse base of institutional capital from across Europe, the Americas, the Middle East, and Asia. This included significant commitments from pension funds, banks, insurance companies, fund of funds, and family offices, with a notable blend of substantial re-investment from existing limited partners and fresh capital from new entrants.

Reflecting a growing emphasis on responsible investment, Fremman II MM is designated as an Article 8 fund under the EU's Sustainable Finance Disclosure Regulation (SFDR). This classification signals the firm's integration of sustainability considerations into its investment process. The fund has already initiated its deployment strategy, having committed capital to five distinct platform companies. These include Rehaneo, a German provider of rehabilitation and occupational health services; Diesse, an Italian specialist in in-vitro diagnostics; Stingray Healthcare, a European radiotherapy platform; AGQ Labs, a global testing and inspection services firm; and Bertin Technologies, a European leader in advanced measurement systems for critical sectors.

The successful closing of Fremman II MM coincides with another significant milestone for the firm: the finalization of its Special Opportunities Fund I (SOF I). This continuation vehicle was established to support the ongoing growth of Kids Planet, a prominent UK-based nursery operator, demonstrating Fremman's capacity for tailored capital solutions.

Fremman Capital's inaugural fund, Fremman I MM, which raised over €600 million and an additional €400 million in co-investment capital, was recognized as the largest first-time pan-European buyout fund launched post-Covid. Its portfolio included notable companies such as Bollo Natural Fruit, VPS, Palex Medical, Kids Planet, and Medinet.

With a strategic presence across five European hubs—London, Luxembourg, Madrid, Munich, and Paris—Fremman Capital leverages the expertise of its approximately 40 professionals. This international team, representing 12 nationalities, brings over a century of combined investment experience to bear on its mid-market buyout strategy. Jefferies acted as the financial advisor, while Paul Weiss Rifkind Wharton and Garrison provided legal counsel for the transaction.